<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02335021</url>
  </required_header>
  <id_info>
    <org_study_id>0405026766-2</org_study_id>
    <nct_id>NCT02335021</nct_id>
  </id_info>
  <brief_title>The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adults</brief_title>
  <acronym>AFS-adult</acronym>
  <official_title>The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of dietary exposure to artificial
      sweeteners on taste sensitivity, preference and brain response in adults. The investigators
      hypothesize that dietary exposure to artificial sweeteners (sucralose) will decrease
      sensitivity to taste, shift preference of sweet and savory taste to a higher dose, and reduce
      brain response in amygdala to sweet taste compared to sucrose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We aim to identify neural factors that contribute to taste intensity perception in humans and
      to determine environmental mechanisms that contribute to variation in taste sensitivity.
      Significant controversy surrounds the possibility that consumption of artificial sweeteners
      (AFS) leads to weight gain. Given that the five FDA approved AFSs are found in thousands of
      foods (Yang 2010) this marks a clear and significant gap in knowledge. Our preliminary data
      demonstrate a 3-fold decrease in sweet taste sensitivity following consumption of a beverage
      sweetened with two packets of Splenda for just 10 days. These data provide strong evidence
      that repeated exposure to sucralose reduces perception of sweet taste intensity, most likely
      by down-regulation of the sweet taste receptor. Therefore, it is imperative that we gain a
      greater understanding of the physiological consequences of AFS, since alterations in sweet
      taste perception, metabolism and brain reward that occur in response to AFS exposure may
      promote weight gain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">April 24, 2019</completion_date>
  <primary_completion_date type="Actual">April 24, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratings of taste sensitivity</measure>
    <time_frame>up to one week after intervention</time_frame>
    <description>general labeled magnitude scale ratings of taste intensity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ad libitum food intake</measure>
    <time_frame>up to one week after intervention</time_frame>
    <description>amount of Mac&amp;Cheese consumed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>brain response to taste stimuli</measure>
    <time_frame>up to one week after intervention</time_frame>
    <description>BOLD response as measured by fMRI</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Impairment of Oral Perception</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Sucralose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucralose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sucrose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucrose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sucralose + maltodextrin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with Splenda + maltodextrin .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sucralose + Sucrose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with Splenda + sucrose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sucralose</intervention_name>
    <description>2 packets per 12 fl oz</description>
    <arm_group_label>Sucralose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sucrose</intervention_name>
    <description>equisweet to sucralose</description>
    <arm_group_label>Sucrose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sucralose + maltodextrin</intervention_name>
    <description>sucralose plus equicaloric (to sucrose) maltodextrin</description>
    <arm_group_label>Sucralose + maltodextrin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sucralose + Sucrose</intervention_name>
    <description>half the amount of sucralose plus equicaloric sucrose</description>
    <arm_group_label>Sucralose + Sucrose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy

          -  Fluent in English

          -  Right handed

        Exclusion Criteria:

          -  History of oral nerve damage,

          -  presence of known taste or smell disorder,

          -  food allergies or sensitivities (for example nuts, lactose, artificial sweeteners),

          -  history of CNS disease,

          -  diabetes,

          -  history of DSM-IV major psychiatric disorder,

          -  including alcohol and substance abuse,

          -  chronic use of medication that may affect taste,

          -  conditions that may interfere with gustatory or olfactory perception (colds, seasonal
             allergies,

          -  recent smoking history),

          -  aberrant stimulus ratings,

          -  contra-indication for fMRI,

          -  uncomfortable swallowing in supine position,

          -  discomfort or anxiety associated with insertion an intravenous catheter,

          -  regular artificial sweetener use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dana M Small</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 24, 2014</study_first_submitted>
  <study_first_submitted_qc>January 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2015</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data will be publicly shared at publication of manuscript.</ipd_description>
    <ipd_time_frame>De-identified data will be publicly shared at publication of manuscript (anticipated in 2019). Data will be available indefinitely, or at least as long as the hosting platform is available.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

